MPR Weekly Dose Podcast Episode 105

This week: Use of monoclonal antibodies restricted due to Omicron; Veklury given the go-ahead as an outpatient treatment; Parsaclisib’s NDA withdrawn; New data produces a reconsideration for Pepaxto withdrawal; And there’s a new treatment approval for unresectable or metastatic uveal melanoma.

MPR Weekly Dose Podcast Episode 103

This week news of a new treatment for insomnia; The FDA comment on magnesium hypertension claims; Transmucosal buprenorphine linked to dental decay; Researchers assess changes in menstrual cycles in relation to COVID vaccines; And experts have their say on the best diets for 2022.

MPR Weekly Dose Podcast Episode 102

Contraindication added to Janssen COVID-19 vaccine; Pfizer announce final results for their COVID-19 oral antiviral; A new treatment for benign prostatic hyperplasia; REMS change for CAR T-cell therapy, and Rinvoq gains approval for active psoriatic arthritis. 

MPR Weekly Dose Podcast Episode 101

This week Evusheld has become the first pre-exposure prophylaxis for COVID-19; Data shows that the Pfizer-BioNTech booster dose ups protection against Omicron; Monoclonal antibody therapy is authorized for children; Heterologous boosting may be more beneficial than homogeneous; And important information regarding Veklury.

MPR Weekly Dose Podcast Episode 99

This week on the pod, there’s positive news for the COVID-19 oral antiviral candidate, Paxlovid; The CDC expands a recall for aromatherapy sprays connected to fatal cases of a rare tropical disease; The first eye drop to treat presbyopia is approved; An alternative to naloxone gets fast tracked; And a study compares the migraine treatments erenumab and topiramate. 

MPR Weekly Dose Podcast Episode 98

FDA Advisory Committee votes on whether the Pfizer-BioNTech vaccine should be authorized in 5 to 11 year olds; The Moderna vaccine elicits strong antibody responses in pediatrics; Trial results shed light on booster dose efficacy; Shingrix is recommended for immunocompromised patients; A novel treatment is approved for macular edema associated with uveitis; And Pepaxto is withdrawn following new findings.

MPR Weekly Dose Podcast Episode 97

This week: The FDA authorize boosters for Moderna and Janssen and okay ‘mixing and matching’ of vaccines for the booster dose. The first interchangeable biosimilar to Humira is approved. Also there’s approvals in dry eye disease, pain management and opioid overdoses. 

MPR Weekly Dose Podcast Episode 96

This week the USPSTF update aspirin recommendations for those 60 years and older; The FDA take a stance on needle-free devices for injecting dermal fillers; REMS requirements are updated for isotretinoin products; A new treatment is approved for pediatric congenital athymia; An Emergency Use request is submitted for an oral antiviral COVID treatment; And the FDA advisory panel vote on boosters for the Moderna vaccine.